A study of the CEDIA digoxin immunoassay

Area of Science:

• Clinical Chemistry
• Biotechnology
• Immunoassay Development

Background:

• Digoxin is a cardiac glycoside used to treat heart failure and arrhythmias.
• Accurate monitoring of digoxin levels is crucial due to its narrow therapeutic index.
• Existing methods like radioimmunoassay (RIA) can be time-consuming and require specialized handling.

Purpose of the Study:

• To evaluate the performance of the CEDIA digoxin immunoassay on the Cobas-Bio centrifugal analyzer.
• To assess the correlation between the CEDIA assay and RIA for digoxin quantification.
• To determine the precision, stability, and efficiency of the CEDIA assay.

Main Methods:

• The CEDIA digoxin immunoassay was performed using the Cobas-Bio centrifugal analyzer.
• Enzyme activity was measured based on the recombination of beta-galactosidase fragments.
• Assays were conducted on sera with known digoxin concentrations and compared against RIA results.

Main Results:

• Enzyme activity showed a direct proportionality to digoxin concentration.
• CEDIA results correlated well with RIA (r = 0.95), with the equation: CEDIA (microgram/L) = 1.00 x RIA - 0.06 microgram/L.
• Within-run coefficients of variation (CVs) were 1-3%, and day-to-day CVs were 3-12%.
• Reagents demonstrated stability for at least one month at 5°C.
• The assay processed samples approximately twice as fast as RIA.

Conclusions:

• The CEDIA digoxin immunoassay is a precise and accurate method for digoxin measurement.
• It offers a significant time advantage over RIA, making it suitable for high-throughput clinical laboratories.
• The assay's stability and performance on the Cobas-Bio analyzer support its clinical utility.